吉非替尼治疗化疗失败的晚期非小细胞肺癌疗效观察

Clinical Observation of Gefitinib in the Treatment of Advanced Non-small Cell Lung Cancer Failed to Respond Previous Chemotherapy

目的观察吉非替尼治疗化疗失败的晚期非小细胞肺癌(NSCLC)的疗效及毒副反应。方法对32例化疗失败的晚期NSCLC患者给予吉非替尼250 mg,口服,每天1次,至病情进展或出现不可耐受的毒副反应。结果 32例患者中,CR 0例(0.00%),PR 8例(25.00%),SD 13例(40.62%),PD 11例(34.38%),有效率为25.00%,疾病控制率为65.62%,中位疾病进展时间为5.2个月,中位生存时间为9.3个月,1 a生存率为34.38%。结论吉非替尼治疗晚期NSCLC有较好的疗效,毒副反应可耐受。

Objective To observe the efficacy and toxicities of gefitinib in the treatment of advanced non-small cell lung cancer failed to respond previous chemotherapy. Methods Thirty-two patients with non-small cell lung cancer failed to respond previous chemotherapy were treated with gefitinib, the gefitinib was given as a single drug at a dose of 250 mg per day orally until disease progressed or unacceptable toxieities occurred. Results Among the 32 eases,CR was observed in the 0 case （0.00%） ,PR 8 cases （25.00%） ,SD 13 cases （40.62%） ,PD ll cases （34.38%） ,the response rate was 2：5.00% , the disease control rate was 65.62%. The median survival time was 5.2 months, the median time to progression was 9.3 months. The one-year survival rate was 34.38%. Conclusion Gefitinib takes the better effects on the patients with advanced NSCLC,and the toxieities are tolerated.